528 692
Obtaining funding:
None.
Administrative, technical, or material support:
None.
Supervision:
Barentsz, Bosch.
Other:
None.
Financial disclosures:
Olivier Wegelin certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony,
royalties, or patents filed, received, or pending), are the following:
None.
Funding/Support and role of the sponsor:
None.
Appendix 1
Complete search query
Date of search: 27-10-2014
Search performed by: Carla Sloof (
c.sloof@ antoniusziekenhuis.nl).
PubMed
(‘‘Prostate’’[Mesh] OR ‘‘Prostatic Neoplasms’’[Mesh] OR
prostat*[tiab]) AND (‘‘Biopsy’’[Mesh] OR biops*[tiab])
AND (‘‘Magnetic Resonance Imaging’’[Mesh] OR ‘‘Image-
Guided Biopsy’’[Mesh] OR magnetic resonance[tiab] OR
MRI*[tiab] OR MR imag*[tiab] OR MR guid*[tiab] OR MR
target*[tiab] OR MR-US[tiab] OR MRUS[tiab] OR MR-
TRUS[tiab] OR mpMR*[tiab] OR image guid*[tiab] OR
imaging guid*[tiab] OR fusion-guid*[tiab] OR multiparame-
tric[tiab] OR image fusion[tiab] OR ultrasound fusion[tiab]
OR US fusion[tiab])
NOT (review[pt] OR case reports[pt]) AND
(2004:2014[pdat])
1138 hits
Embase
‘prostate’/de OR ‘prostate tumor’/exp OR prostat*:ab,ti AND
(‘biopsy’/exp OR biops*:ab,ti) AND (‘nuclear magnetic
resonance imaging’/exp OR ‘image guided biopsy’/exp OR
‘magnetic resonance’:ab,ti OR mri*:ab,ti OR (mr NEXT/1
(imag* OR guid* OR target* OR us OR trus)):ab,ti OR
mrus:ab,ti OR mpmr*:ab,ti OR ((image OR imaging OR
fusion) NEXT/1 guid*):ab,ti OR multiparametric:ab,ti OR
‘image fusion’:ab,ti OR ‘ultrasound fusion’:ab,ti OR ‘us
fusion’:ab,ti)
NOT ([conference abstract]/lim OR [conference
paper]/lim OR [conference review]/lim OR [review]/lim OR
‘case report’/de) AND [1–1–2004]/sd
1378 hits
CENTRAL
prostat* and biops* and (‘magnetic resonance’ or mri* or (mr
next/1 (imag* or guid* or target* or us or trus)) or mrus or
mpmr* or ((image or imaging or fusion) next/1 guid*) or
multiparametric or ‘image fusion’ or ‘ultrasound fusion’ or
‘us fusion’)
Filters: Publication Year from 2004 to 2014
46 hits
Total hits three databases: 2562 references
Appendix 2
Summary of results of additional papers from cursory repeat search.
Author; yr of
publication
Population
investigated
No. of
patients
Mean
age
(yr)
Mean
PSA
(ng/ml)
MRI acquisition
according to ESUR
guidelines; MRI used
Threshold for
target biopsy
Biopsy
method;
approach
Definition of
clinically
significant PCa
No. of patients
SB No. patients TB
Sensitivity
all cancer
Sensitivity
significant cancer
Peltier et al.,
2015
[46]
No prior
biopsy
110
65.1 8.4
Yes; Magnetom
Verio (Siemens);
3 Tesla
In tumour suspicious/
abnormal MRI;
no threshold defined
MRI/TRUS
fusion;
transrectal
-Gleason score
3 + 4 -or Gleason
3 + 3 and MMCL
6 mm
SB:
n
= 110
TB:
n
= 100
SB: 72.5% (50/69)
TB: 82.6% (57/69)
SB: 61.5% (32/52)
TB: 98.1% (51/52)
p
= 0.0008
Quentin et al.,
2014
[47]
No prior
biopsy
128
66.1 8.7
Yes; Magnetom
Trio (Siemens);
3 Tesla
No threshold
defined
In-bore MRI;
transrectal
-Gleason score
3+ 4 -MCCL
>
5 mm
SB:
n
= 128
TB:
n
= 128
SB: 87.25% (68/78)
TB: 87.25% (68/78)
SB: 80.6% (54/67)
TB: 86.6% (58/67)
Radtke et al.,
2015
[48]
Negative
or no prior
biopsy
294
64
7.3
Yes;
Unknown
(Siemens); 3 Tesla
PIRADS 2 or
higher
MRI/TRUS
fusion;
transperineal
-Gleason score
I
3 + 4
SB:
n
= 294
TB:
n
= 196
SB: 90% (135/150)
TB: 74.7% (112/150)
p
= 0.001
SB: 79.1% (68/86)
TB: 87.2% (75/86)
Siddiqui et al.,
2015
[49]
Negative
or no prior
biopsy
1003 62.1 6.7
Yes;
Achieva (Philips);
3 Tesla
In tumour suspicious/
abnormal MRI; no
threshold defined
MRI/TRUS
fusion;
transrectal
-Gleason score
4 + 3 -or Gleason
score = 3 + 4 and
>
50% core positivity
SB:
n
= 1003
TB:
n
= 1003
SB: 83.2% (469/564)
TB: 81.7% (461/564)
SB: 69.4% (211/304)
TB: 81.6% (248/304)
p
<
0.001
ESUR = European Society of Urogenital Radiology; MMCL = maximum cancer core length; MRI = magnetic resonance imaging; PCa = prostate cancer; PIRADS = prostate imaging reporting and data system; SB = systematic
biopsy; TB = target biopsy; TCCL = total cancer core length; TRUS = transrectal ultrasound.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 5 1 7 – 5 3 1
528